Related Experiment Video

Updated: Jun 18, 2026

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

Insulin pump therapy management in very young children with type 1 diabetes using continuous subcutaneous insulin

Ivana Rabbone1, Andrea Scaramuzza, Adriana Bobbio

  • 1Department of Paediatrics, University of Turin, Italy. ivana.rabbone@unito.it

Diabetes Technology & Therapeutics
|November 13, 2009
PubMed

Insights

Continuous subcutaneous insulin infusion (CSII) improves metabolic control in very young children with type 1 diabetes. Personalizing insulin pump settings is crucial for optimizing therapy in this unique pediatric population.

Area of Science:

  • Pediatric Endocrinology
  • Metabolic Disorders
  • Diabetes Management

Background:

  • Type 1 diabetes in very young children presents unique challenges compared to older age groups.
  • Continuous subcutaneous insulin infusion (CSII) is a key therapy for managing type 1 diabetes.
  • Understanding age-dependent characteristics of CSII is vital for this population.

Purpose of the Study:

  • To analyze age-dependent characteristics and parameters of CSII in children under 6 years with type 1 diabetes.
  • To evaluate the impact of CSII on metabolic control and pump-dependent parameters in this cohort.

Main Methods:

  • Retrospective evaluation of 46 children with type 1 diabetes undergoing CSII.
  • Analysis of metabolic control (HbA1c) and pump parameters after approximately 0.89 years of CSII therapy.

Main Results:

  • CSII significantly improved metabolic control, with glycosylated hemoglobin levels decreasing from 8.12% to 7.30% (P < 0.05).
  • No increased risk of diabetic ketoacidosis or hypoglycemia was observed.
  • Very young patients required larger insulin boluses, particularly for morning and afternoon meals/snacks.

Conclusions:

  • CSII therapy can effectively improve glycemic control in very young children with type 1 diabetes.
  • Personalization of insulin pump settings, especially bolus doses, is essential for optimizing CSII outcomes in this age group.
  • Further research into tailored CSII parameters is needed for this unique pediatric population.
Abstract

More Related Videos

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain08:32

Studying the Hypothalamic Insulin Signal to Peripheral Glucose Intolerance with a Continuous Drug Infusion System into the Mouse Brain

Published on: January 4, 2018

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into rapid-acting...
Diabetes Mellitus: Overview and Type I Subtype01:22

Diabetes Mellitus: Overview and Type I Subtype

Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Diabetes: Management and Pharmacotherapy01:15

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...